Because they observed that overall survival (OS) was associated with the mutant allele burden in AML, their data restricted the list of gene mutations, finally including DNMT3A, TET2, ASXL1, RUNX1, and IDH1/2, shown to be useful in MRD-based prognostication in AML [44]. This evidence concerns the gene IDH1 and acute myeloid leukemia.